Related Experiment Videos
Low-grade endometrial stromal sarcoma recurring over three decades.
S L Styron1, T W Burke, W K Linville
1Department of Obstetrics and Gynecology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234-6200.
Gynecologic Oncology
|November 1, 1989
Summary
This case study highlights a rare, low-grade endometrial stromal sarcoma (ESS) recurring over 29 years. Progestin therapy showed promise for recurrent, hormone receptor-positive ESS.
Area of Science:
- Gynecologic Oncology
- Surgical Pathology
- Endocrinology
Background:
- Endometrial stromal sarcoma (ESS) is a rare uterine malignancy with variable clinical behavior.
- Low-grade ESS often presents indolently, posing challenges in long-term management.
Observation:
- A patient with low-grade ESS underwent a third resection 29 years after initial diagnosis.
- Recurrent tumor tissue demonstrated high estrogen and progesterone receptor levels and diploid DNA content.
- The patient received prior vincristine chemotherapy and is currently treated with megestrol acetate.
Findings:
- Mitotic activity is a key prognostic indicator differentiating high- and low-grade ESS.
- Surgical excision remains the primary treatment for ESS.
- Progestational agents may be effective for recurrent or persistent disease in hormone receptor-positive ESS patients.
Implications:
- Indolent ESS may necessitate prolonged surveillance and multimodal treatment strategies.
- Hormone receptor status is crucial for selecting adjuvant therapies in recurrent ESS.
- Long-term management aims to maintain patient function despite recurrent disease.